Steven M. Skolnick

New York / New Jersey

T: +1 973.597.2476 | F: +1 973.597.2477 sskolnick@lowenstein.com

New York / New Jersey

T: +1 973.597.2476 | F: +1 973.597.2477 sskolnick@lowenstein.com

Related Areas

Education

St. John's University School of Law (J.D. 1993), cum laude

Amherst College (B.A. 1988)

Admissions

New York
New Jersey

BIO
EXPERIENCE
HONORS & AWARDS
NEWS & INSIGHTS

Filter By

Section

Type:

Practices:

Sectors:

Start Date:

End Date:

Steven has extensive legal experience focusing on capital markets transactions and securities law matters, representing public companies, investment banks, and investors. Steven also handles strategic mergers and acquisitions, representing both public and private companies.

When managing public and private securities offerings, Steven identifies and mitigates potential roadblocks, ensuring that transactions move forward quickly. Issuers, underwriters, and investors all appreciate Steven's informed perspective, diplomacy, and ability to expedite transactions.

Steven's involvement with capital markets transactions touches upon nearly every industry sector. He frequently handles IPO transactions, follow-up public offering deals, CMPO transactions, Special Purpose Acquisition Companies (SPACs), registered direct offerings, ATMs, PIPE deals, convertible equity transactions, and debt offerings.

Steven's track record of success in the life sciences sector makes him an essential team player for life sciences transactions. He works with leading investment banks that concentrate in this industry, deftly handling public offerings of biopharmaceuticals and medical technology companies, as well as other transactions.

Steven often serves as an advisor to corporate companies and their boards on matters such as SEC compliance, disclosure issues, and corporate governance. He also counsels clients on federal securities law, as well as rules and regulations pertaining to the Financial Industry Regulatory Authority, Nasdaq, and the New York Stock Exchange.

Principal areas of focus include:

Capital markets
Securities law
Mergers and acquisitions
Governance

EXPERIENCE

Select Capital Markets & Securities Experience:

Represented H.C. Wainwright & Co., as exclusive placement agent, in connection with a $61 million registered direct offering of common stock of Caladrius Biosciences, Inc. (NASDAQ: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease.
Represented Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, in connection with an At-the-Market offering with an aggregate offering price of up to $50 million.
Represented Oppenheimer & Co., Inc. and William Blair and Company, L.L.C. as sales agents in connection with a $50 million At-the-Market offering of Brickell Biotech (NASDAQ: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases.
Represented BTIG, LLC, as sole book-running manager, in connection with a $42 million underwritten public offering of common stock of OncoSec Medical Incorporated (NASDAQ:ONCS), a late-stage biotechnology company.
Represented Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, in connection with a $30 million underwritten public offering of common stock and warrants.
Represented AzurRx Biopharma (NASDAQ: AZRX), a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders, in connection with a private placement of convertible preferred stock and warrants and exchange of, as consideration in the private placement, its outstanding convertible promissory notes, for a combined value of $22.1 million.
Represented Aeterna Zentaris Inc. (NASDAQ: AEZS), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, in connection with a $29.7 underwritten offering of common stock.
Represented Provention Bio, Inc. (NASDAQ: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, in connection with a $110 million underwritten public offering of common stock.
Represented Roka Bioscience Inc. in connection with its $60 million initial public offering led by Bank of America and Leerink Partners.
Represented Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, in connection with an At-the-Market-Offering of shares of common stock for up to $150 million.
Represented Motus GI Holdings, Inc. in connection with its $18 million initial public offering led by Piper Jaffray and Oppenheimer & Co.
Represented Roth Capital Partners as underwriter in connection with a $26.5 million underwritten public offering of common stock of Loop Industries Inc. (NASDAQ: LOOP), an innovator in sustainable plastics technology.
Represented Oppenheimer & Co., as sole book-running manager, in connection with a $20 million underwritten offering of common stock and warrants for Brickell Biotech, Inc., (NASDAQ: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases.
Represented Provention Bio (NASDAQ:PRVB), a clinical stage biopharmaceutical company, based in New Jersey, dedicated to intercepting and preventing immune-mediated diseases, in its $63.9 million initial public offering of shares of common stock.
Represented H.C. Wainwright & Co., as exclusive lead placement agent, in connection with a $25 million public offering of common stock for Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company.
Represented Kintara Therapeutics, Inc. (NASDAQ: KTRA), formerly DelMar Pharmaceuticals, Inc., developer of novel cancer therapies for patients with unmet medical needs, in connection with a $25 million private placement of Series C Convertible Preferred Stock priced at-the-market.
Represented Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, in connection with an At-the-Market offering with an aggregate offering price of up to $50 million.
Represented Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, in connection with an at-the-market offering of common stock of up to $75 million.
Represented H.C. Wainwright & Co. as the sole book-running manager in connection with the $31.6 million underwritten public offering of common stock of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company developing Antibody Radiation-Conjugates.
Represented Matinas BioPharma Holdings, Inc. (NYSE:MTNB) in connection with a clinical stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, in connection with an approximately $50 million public offering of common stock.
Represented H.C. Wainwright & Co., LLC, as the underwriter, in connection with a $28.75 million public offering for Onconova Therapeutics, Inc. (Nasdaq: ONTX).
Represented Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, in connection with a $46 million underwritten public offering of common stock.

Representing Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, in its pending acquisition of Senlang Bio in an all-stock transaction valued at approximately $98 million.
Represented Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, in connection with a definitive agreement and plan of merger for a business combination with Tenzing Acquisition Corp. (NASDAQ: TZAC), a special purpose acquisition (SPAC), resulting in a total post-money equity value of the combined company of approximately $119 million.
Represented LifeCell Corporation (NASDAQ:LIFC) in its $1.7 billion sale to Kinetic Concepts, Inc. (NYSE: KCI).
Represented Arotech Corporation (NASDAQGM: ARTX) in connection with its definitive agreement with a Greenbriar Equity Group, L.P. affiliate to acquire all outstanding shares of Arotech common stock for an aggregate equity value of approximately $80.8 million.
Represented Delmar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, in connection with the acquisition of Adgero Biopharmaceuticals Holdings, Inc., a privately held biopharmaceutical company focused on the development of its late stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. Upon closing, DelMar changed its name to Kintara Therapeutics, Inc. and began trading on Nasdaq under the new ticker symbol "KTRA."
Represented Timber Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, in connection with its definitive merger with BioPharmX Corporation. Under the terms of the merger agreement, Timber Pharmaceuticals LLC merged into a wholly owned subsidiary of BioPharmX, with Timber surviving as a wholly owned subsidiary of BioPharmX. The combined company operates under the name Timber Pharmaceuticals, Inc., with its shares trading on the NYSE American under the ticker symbol "TMBR."
Represented Sonnet BioTherapeutics, Inc., a privately-held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, in connection with its merger with Chanticleer Holdings, Inc. to form a company operating under the name Sonnet BioTherapeutics Holdings, Inc., with its shares trading on the Nasdaq Capital Market under the ticker symbol “SONN” and in connection with a private placement of $19 million and the acquisition of the global development rights for Atexakin Alfa from Relief Therapeutics SA.

HONORS & AWARDS

The Best Lawyers in America (2013-2023)
Recognized in the Corporate Law and Securities / Capital Markets Law sections
LMG Life Sciences Star (2020-2022)
Recognized in the Corporate and Licensing & Collaboration sections
The BTI Consulting Group: BTI Client Service All-Stars (2013)
One of only 307 lawyers to be named to the “BTI Client Service All-Stars” for providing outstanding client service.

CLICK HERE FOR AWARD INFORMATION & METHODOLOGY

No aspect of this or any advertisement has been approved by the Supreme Court of California, the District of Columbia Court of Appeals, the Supreme Court of New Jersey, the New York State Court of Appeals, or the Utah Supreme Court.

NEWS & INSIGHTS

Education

St. John's University School of Law (J.D. 1993), cum laude

Amherst College (B.A. 1988)

Admissions

New York
New Jersey

Recent Searches

Relevant Insights

PROFESSIONALS | Lawyers

NEWS & INSIGHTS | Firm News

NEWS & INSIGHTS | Publications

Featured Content

VENTURE CAPITAL / Firm News

Video

VENTURE CAPITAL / Firm News